Oleg Gluz, Sherko Kuemmel, Ulrike Nitz, Michael Wilhelm Braun, Kerstin Luedtke-Heckenkamp, Maren Darsow, Helmut Forstbauer, Bahriye Aktas, Eva-Maria Grischke, Claudia Schumacher, Toralf Reimer, Wolfram Malter, Benno Nuding, Rachel Wuerstlein, Matthias Christgen, Hans Heinrich Kreipe, Ronald E. Kates, Christine zu Eulenburg, Rick Baehner, Nadia Harbeck. "Role of neoadjuvant versus adjuvant chemotherapy, dose density, and treatment schedule in biologically high-risk HR+/HER2- breast cancer: A pooled analysis of the WSG ADAPT-HR+/HER2- and PlanB trials.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.17_suppl.lba515